secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theseus Pharmaceuticals, Inc. (—)
CIK:        0001745020
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001745020-23-000073
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theseus Pharma lays off 72% of staff, explores strategic alternatives; cash $225.4M
--------------------------------------------------------------------------------

- Workforce reduction of ~72% (26 employees, including R&D President); severance costs ~$5.5M in Q4 2023.
- Process to explore strategic alternatives including potential sale of company or assets to maximize shareholder value.
- Cash, cash equivalents, and marketable securities total $225.4M as of September 30, 2023.
- President R&D William Shakespeare terminated without cause; receives $0.5M severance, accelerated equity vesting, consulting role through June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745020/000174502023000073/0001745020-23-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745020/000174502023000073/thrx-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001745020-23-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer